ORLANDO, Fla.—Early docetaxel followed by abiraterone may be better than the other way around for the treatment of metastatic castration-resistant prostate cancer (mCRPC), according to new study findings presented at the 2015 Genitourinary Cancers Symposium.
Emmanuel S. Antonarakis, MD, assistant professor of oncology at Johns Hopkins University in Baltimore, and colleagues reviewed the records of 86 mCRPC patients at the hospital. Of these, 53 received docetaxel followed by abiraterone and 33 received the reverse sequence.
“Men receiving docetaxel followed by abiraterone had superior progression-free survival and overall survival outcomes compared with men who received abiraterone followed by docetaxel,” Dr. Antonarakis told Renal & Urology News. “What’s more, men receiving docetaxel first had less favorable baseline clinical characteristics than men who received abiraterone first, yet their outcomes were still better after multivariable adjustments.”
Progression-free survival was nearly 9 months longer in the docetaxel-abiraterone group (median 19.1 vs. 10.4 months).Overall survival was about 1 year longer in the docetaxel first group (median 30.3 vs. 18.2 months).
The results are in line with results of the CHAARTED trial, which showed improved survival after early docetaxel treatment in metastatic hormone-sensitive prostate cancer, the researchers noted.
“These retrospective data should spark interest in designing prospective, randomized trials to formally test the sequencing of docetaxel and abiraterone,” Dr. Antonarakis said.